RAPT Therapeutics. has been granted a patent for crystalline forms of a CCR4 antagonist, including oral dosage forms and methods for their preparation and use. The patent specifically claims a compound with a detailed chemical structure, highlighting its potential therapeutic applications. GlobalData’s report on RAPT Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on RAPT Therapeutics, Peptide pharmacophores was a key innovation area identified from patents. RAPT Therapeutics's grant share as of June 2024 was 31%. Grant share is based on the ratio of number of grants to total number of patents.
Crystalline ccr4 antagonist compound and oral dosage forms
The granted patent US12006318B2 describes a novel crystalline compound, specifically 2-((R)-3-(1-(1-((R)-1-(2,4-Dichlorophenyl)ethyl)-3-(trifluoromethyl)-1H-pyrazolo[3,4-13]pyrazin-6-yl)azetidin-3-yl)piperidin-1-yl)ethan-1-ol benzene sulfonate. The patent outlines various claims related to the compound's structural characteristics, including its unique X-ray powder diffractogram absorption peaks and melting point, which ranges from approximately 170°C to 173°C. The compound exhibits specific absorption peaks at various 2? angles, indicating its crystalline nature and providing a means for characterization through X-ray diffraction techniques.
Additionally, the patent includes claims for pharmaceutical compositions containing the crystalline compound, which may be formulated with various excipients and agents, such as sodium lauryl sulfate and lactose mono-hydrate. These compositions are intended for oral administration and can be designed in tablet form, with specified dosages of 25 mg or 75 mg of the crystalline compound. The patent also outlines methods for treating a range of immune, inflammatory, and cancer-related diseases, emphasizing the compound's potential therapeutic applications. Notably, the methods may involve co-administration with other therapeutic agents, including pembrolizumab, to enhance treatment efficacy for conditions such as autoimmune diseases, allergies, and various cancers.
To know more about GlobalData’s detailed insights on RAPT Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
